Related Experiment Video
Updated: Nov 10, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
The medical treatment of cardiogenic shock: cardiovascular drugs
Daniel De Backer1, Julian Arias Ortiz2, Bruno Levy3,4,5
1Department of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles, Brussels, Belgium.
Insights
Norepinephrine is the recommended first-line vasopressor for cardiogenic shock, offering the best outcomes. Dobutamine is a primary inotropic agent, with levosimendan as a valuable alternative for non-responsive cases.
Area of Science:
- Cardiology
- Critical Care Medicine
- Pharmacology
Background:
- Cardiogenic shock necessitates inotropic and vasopressor agents to restore tissue perfusion.
- Current therapeutic strategies are evolving with recent clinical findings.
Purpose of the Study:
- To review the current applications of vasopressors and inotropes in managing cardiogenic shock.
- To delineate the roles and efficacy of different pharmacological agents.
Main Methods:
- Review of recent literature and guidelines on vasopressor and inotrope use in cardiogenic shock.
- Analysis of comparative effectiveness and safety profiles of various agents.
Main Results:
- Norepinephrine is identified as the preferred first-line vasopressor due to favorable outcomes and minimal adverse effects.
- Epinephrine use is linked to increased refractory shock and mortality risk.
- Vasopressin presents a viable option for specific patient subsets, such as those with tachycardia or pulmonary hypertension.
- Dobutamine is the primary inotropic agent, with levosimendan as an effective alternative or add-on therapy.
- The overall impact of inotropic agents on patient outcomes remains a subject of ongoing research.
Conclusions:
- Norepinephrine is strongly recommended as the initial vasopressor therapy for cardiogenic shock.
- Individualized patient assessment and hemodynamic response are crucial for selecting appropriate inotropic agents.
Purpose Of Review:
To discuss the use of vasopressors and inotropes in cardiogenic shock.
Recent Findings:
The classic form or cardiogenic shock requires administration of inotropic and/or vasopressor agents to try to improve the impaired tissue perfusion. Among vasopressors various alpha-adrenergic agents, vasopressin derivatives and angiotensin can be used. The first-line therapy remains norepinephrine as it is associated with minimal adverse effects and appears to be associated by the best outcome in network meta-analyses. On the contrary, epinephrine is associated with an increased incidence of refractory shock and observational studies suggest an increased risk of death. Vasopressin may be an excellent alternative in tachycardiac patients or in the presence of pulmonary hypertension. Concerning inotropic agents, dobutamine is the first-line agent but levosimendan is an excellent alternative or additional agent in cases not responding to dobutamine. The impact on outcome of inotropic agents remains controversial.
Summary:
Recent studies have refined the position of the various vasopressor and inotropic agents. Norepinephrine is recommended as first-line vasopressor agent by various guidelines. Among inotropic agents, selection between the agents should be individualized and based on the hemodynamic response.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:22Heart Failure Drugs: β-Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure V: Medical Management